Patient and limb outcomes 10 years after endovascular revascularization of the superficial femoral artery for peripheral artery disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) study.
clinical outcomes
endovascular
femoral artery
limb outcomes, peripheral artery disease (PAD)
Journal
Vascular medicine (London, England)
ISSN: 1477-0377
Titre abrégé: Vasc Med
Pays: England
ID NLM: 9610930
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
9
8
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
We aimed to describe patient and limb outcomes in the decade after endovascular revascularization for chronic lower-extremity peripheral artery disease (PAD). We assessed outcomes in patients having endovascular revascularization of the superficial femoral artery in two centers between 2003 and 2011 and followed for a median 9.3 (25-75%: 6.8, 11.1) years. Outcomes included death, myocardial infarction, stroke, repeat limb revascularizations, and amputations. We used competing risks analysis with clustering by patient to determine the hazard ratios (HR) and 95% CI for patients, and procedural characteristics for cause of death, cardiovascular events, and major adverse limb events (MALE). There were 253 index limb revascularizations in 202 patients followed for a median 9.3 years. Patients had intensive medical treatment with 90% on statins and 80% on beta-blockers. During follow up there were 57 (28%) cardiovascular deaths and 62 (31%) noncardiovascular deaths. Of the 253 limbs, 227 (90%) were free of MALE over follow up and 93 (37%) had MALE or minor repeat revascularization. In multivariable models, cardiovascular death significantly associated with critical limb ischemia (HR = 3.21, 95% CI = 1.84, 5.61) and noncardiovascular death with chronic kidney disease (HR = 2.69, 95% CI = 1.68, 4.30), and smoking (HR = 2.75, 95% CI = 1.01, 7.52). MALE or minor repeat revascularization associated with critical limb ischemia (HR = 1.43, 95% CI = 0.84, 2.43), smoking (HR = 2.49, 95% CI = 1.26, 4.90), and lesion length > 200 mm (HR = 1.51, 95% CI = 0.98, 2.33). Among patients with intensive medical therapy, the risk of noncardiovascular death was high and similar to cardiovascular death. Endovascular intervention can have acceptable long-term results. Future studies should evaluate strategies to reduce both cardiovascular and noncardiovascular deaths.
Sections du résumé
BACKGROUND
We aimed to describe patient and limb outcomes in the decade after endovascular revascularization for chronic lower-extremity peripheral artery disease (PAD).
METHODS
We assessed outcomes in patients having endovascular revascularization of the superficial femoral artery in two centers between 2003 and 2011 and followed for a median 9.3 (25-75%: 6.8, 11.1) years. Outcomes included death, myocardial infarction, stroke, repeat limb revascularizations, and amputations. We used competing risks analysis with clustering by patient to determine the hazard ratios (HR) and 95% CI for patients, and procedural characteristics for cause of death, cardiovascular events, and major adverse limb events (MALE).
RESULTS
There were 253 index limb revascularizations in 202 patients followed for a median 9.3 years. Patients had intensive medical treatment with 90% on statins and 80% on beta-blockers. During follow up there were 57 (28%) cardiovascular deaths and 62 (31%) noncardiovascular deaths. Of the 253 limbs, 227 (90%) were free of MALE over follow up and 93 (37%) had MALE or minor repeat revascularization. In multivariable models, cardiovascular death significantly associated with critical limb ischemia (HR = 3.21, 95% CI = 1.84, 5.61) and noncardiovascular death with chronic kidney disease (HR = 2.69, 95% CI = 1.68, 4.30), and smoking (HR = 2.75, 95% CI = 1.01, 7.52). MALE or minor repeat revascularization associated with critical limb ischemia (HR = 1.43, 95% CI = 0.84, 2.43), smoking (HR = 2.49, 95% CI = 1.26, 4.90), and lesion length > 200 mm (HR = 1.51, 95% CI = 0.98, 2.33).
CONCLUSIONS
Among patients with intensive medical therapy, the risk of noncardiovascular death was high and similar to cardiovascular death. Endovascular intervention can have acceptable long-term results. Future studies should evaluate strategies to reduce both cardiovascular and noncardiovascular deaths.
Identifiants
pubmed: 37211818
doi: 10.1177/1358863X231174052
pmc: PMC10527919
mid: NIHMS1922446
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-298Subventions
Organisme : CSRD VA
ID : I01 CX001549
Pays : United States
Références
J Am Coll Cardiol. 2018 Aug 28;72(9):999-1011
pubmed: 30139446
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Circulation. 2016 Mar 8;133(10):997-1005
pubmed: 26826179
Circulation. 2018 Jan 23;137(4):338-350
pubmed: 29133605
Popul Health Metr. 2006 Jul 06;4:7
pubmed: 16824220
JAMA Intern Med. 2021 Aug 1;181(8):1071-1080
pubmed: 33993204
J Am Heart Assoc. 2016 Jul 08;5(7):
pubmed: 27402237
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Circ Cardiovasc Interv. 2019 Jun;12(6):e007702
pubmed: 31195825
J Vasc Interv Radiol. 2020 Apr;31(4):614-621.e2
pubmed: 32127322
J Vasc Surg. 2014 Dec;60(6):1565-71
pubmed: 25282696
J Rehabil Res Dev. 2010;47(8):781-95
pubmed: 21110252
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):102-8
pubmed: 25616822
J Vasc Surg. 2015 Sep;62(3):655-64.e8
pubmed: 26215708
J Am Coll Cardiol. 2018 Oct 2;72(14):1563-1572
pubmed: 30261955
Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483
pubmed: 26969758
Circulation. 2017 Mar 21;135(12):e726-e779
pubmed: 27840333
JACC Cardiovasc Interv. 2016 Oct 24;9(20):2157-2164
pubmed: 27765312
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
J Am Coll Cardiol. 2021 Jul 6;78(1):14-23
pubmed: 34210409
J Am Coll Cardiol. 2019 May 28;73(20):2550-2563
pubmed: 30690141
JACC Cardiovasc Interv. 2019 Jun 24;12(12):1125-1136
pubmed: 31153838
N Engl J Med. 2020 Nov 5;383(19):1838-1847
pubmed: 32865380
J Vasc Surg. 2018 Aug;68(2):527-535.e5
pubmed: 29588132
Lancet. 2018 Jan 20;391(10117):219-229
pubmed: 29132880
Eur J Vasc Endovasc Surg. 2020 Apr;59(4):587-596
pubmed: 31926836